BC Week In Review | Oct 27, 2017
Company News

Fujirebio developing companion diagnostic for Morphotek's farletuzumab

The Morphotek Inc. subsidiary of Eisai Co. Ltd. (Tokyo:4523) granted Fujirebio Inc. (Tokyo, Japan) exclusive, worldwide rights to develop and commercialize the CA125 II assay as a companion diagnostic to identify ovarian cancer patients who...
BC Week In Review | Oct 10, 2016
Company News

Eisai, Eurofarma Laboratorios deal

Eisai’s Morphotek Inc. subsidiary granted Eurofarma exclusive, Latin American rights to develop and commercialize farletuzumab, a humanized IgG1 antibody targeting the folate receptor 1 ( FOLR1 ; FR-alpha ). The product is in a Phase II...
BC Week In Review | Dec 21, 2015
Company News

Eisai, University of Gothenburg deal

Eisai’s Morphotek Inc. subsidiary partnered with the Targeted Alpha Therapy (TAT) Group at the university to research and develop Eisai’s farletuzumab for radio-immunotherapy in ovarian cancer. The humanized IgG1 antibody targeting the folate receptor 1...
BC Week In Review | Dec 14, 2015
Company News

Eisai, Blaze Bioscience deal

Eisai’s Morphotek Inc. subsidiary granted Blaze an exclusive, worldwide license to develop and commercialize a tumor-targeting chlorotoxin derivative linked to a near-infrared diagnostic agent to visualize cancer cells during surgery. The chlorotoxin derivative was isolated...
BC Week In Review | Dec 7, 2015
Clinical News

Amatuximab: Phase II started

Eisai’s Morphotek Inc. subsidiary began the double-blind, placebo-controlled, international Phase II ARTEMIS trial to evaluate 5 mg/kg IV amatuximab once weekly with IV pemetrexed and IV cisplatin given on day 1 of each 3-week cycle...
BC Week In Review | Apr 6, 2015
Clinical News

Farletuzumab: Phase II started

Eisai’s Morphotek Inc. subsidiary began the double-blind, placebo-controlled, international Phase II 003-011 trial to evaluate 5 mg/kg IV farletuzumab weekly in combination with carboplatin and either paclitaxel or pegylated liposomal doxorubicin in about 210 patients...
BC Week In Review | Jun 30, 2014
Company News

Eisai, Sorrento deal

Eisai’s Morphotek Inc. subsidiary and Sorrento’s Concortis Biosystems Inc. subsidiary partnered to generate antibody-drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutics using Concortis’ ADC technology. Morphotek will have an option to license...
BC Week In Review | Oct 14, 2013
Clinical News

MORAb-004: Phase I started

Eisai's Morphotek Inc. subsidiary said the Children's Oncology Group began an open-label, U.S. Phase I trial to evaluate IV MORAb-004 once weekly in about 65 pediatric patients with recurrent or refractory solid tumors. Morphotek has...
BC Week In Review | Jan 21, 2013
Clinical News

Farletuzumab: Preliminary Phase III data

Preliminary data from the double-blind, international Phase III Study FAR 131 (MORAb-003-004) trial in 1,100 patients with platinum-sensitive epithelial ovarian cancer in first relapse showed that IV farletuzumab plus carboplatin and taxane chemotherapy missed the...
BC Extra | Jan 15, 2013
Clinical News

Eisai's farletuzumab misses in ovarian cancer

Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) said IV farletuzumab plus carboplatin and taxane chemotherapy missed the primary endpoint of improving progression-free survival (PFS) vs. placebo plus carboplatin and taxane chemotherapy in the Phase III FAR 131...
Items per page:
1 - 10 of 113
BC Week In Review | Oct 27, 2017
Company News

Fujirebio developing companion diagnostic for Morphotek's farletuzumab

The Morphotek Inc. subsidiary of Eisai Co. Ltd. (Tokyo:4523) granted Fujirebio Inc. (Tokyo, Japan) exclusive, worldwide rights to develop and commercialize the CA125 II assay as a companion diagnostic to identify ovarian cancer patients who...
BC Week In Review | Oct 10, 2016
Company News

Eisai, Eurofarma Laboratorios deal

Eisai’s Morphotek Inc. subsidiary granted Eurofarma exclusive, Latin American rights to develop and commercialize farletuzumab, a humanized IgG1 antibody targeting the folate receptor 1 ( FOLR1 ; FR-alpha ). The product is in a Phase II...
BC Week In Review | Dec 21, 2015
Company News

Eisai, University of Gothenburg deal

Eisai’s Morphotek Inc. subsidiary partnered with the Targeted Alpha Therapy (TAT) Group at the university to research and develop Eisai’s farletuzumab for radio-immunotherapy in ovarian cancer. The humanized IgG1 antibody targeting the folate receptor 1...
BC Week In Review | Dec 14, 2015
Company News

Eisai, Blaze Bioscience deal

Eisai’s Morphotek Inc. subsidiary granted Blaze an exclusive, worldwide license to develop and commercialize a tumor-targeting chlorotoxin derivative linked to a near-infrared diagnostic agent to visualize cancer cells during surgery. The chlorotoxin derivative was isolated...
BC Week In Review | Dec 7, 2015
Clinical News

Amatuximab: Phase II started

Eisai’s Morphotek Inc. subsidiary began the double-blind, placebo-controlled, international Phase II ARTEMIS trial to evaluate 5 mg/kg IV amatuximab once weekly with IV pemetrexed and IV cisplatin given on day 1 of each 3-week cycle...
BC Week In Review | Apr 6, 2015
Clinical News

Farletuzumab: Phase II started

Eisai’s Morphotek Inc. subsidiary began the double-blind, placebo-controlled, international Phase II 003-011 trial to evaluate 5 mg/kg IV farletuzumab weekly in combination with carboplatin and either paclitaxel or pegylated liposomal doxorubicin in about 210 patients...
BC Week In Review | Jun 30, 2014
Company News

Eisai, Sorrento deal

Eisai’s Morphotek Inc. subsidiary and Sorrento’s Concortis Biosystems Inc. subsidiary partnered to generate antibody-drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutics using Concortis’ ADC technology. Morphotek will have an option to license...
BC Week In Review | Oct 14, 2013
Clinical News

MORAb-004: Phase I started

Eisai's Morphotek Inc. subsidiary said the Children's Oncology Group began an open-label, U.S. Phase I trial to evaluate IV MORAb-004 once weekly in about 65 pediatric patients with recurrent or refractory solid tumors. Morphotek has...
BC Week In Review | Jan 21, 2013
Clinical News

Farletuzumab: Preliminary Phase III data

Preliminary data from the double-blind, international Phase III Study FAR 131 (MORAb-003-004) trial in 1,100 patients with platinum-sensitive epithelial ovarian cancer in first relapse showed that IV farletuzumab plus carboplatin and taxane chemotherapy missed the...
BC Extra | Jan 15, 2013
Clinical News

Eisai's farletuzumab misses in ovarian cancer

Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) said IV farletuzumab plus carboplatin and taxane chemotherapy missed the primary endpoint of improving progression-free survival (PFS) vs. placebo plus carboplatin and taxane chemotherapy in the Phase III FAR 131...
Items per page:
1 - 10 of 113